Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Learning the interaction rules of antibody-antigen binding

Project description

Antibody-antigen binding interaction rules to advance vaccine design

Antibody-antigen binding is fundamental to monoclonal antibodies and vaccines. To accelerate therapeutic discovery, in silico design of antibodies (Ab) and antigens (Ag) must be conducted while addressing the challenge of predicting Ab-Ag binding interactions. Currently, prediction performance for Ab-Ag binding is limited, and the rules governing these interactions remain largely unknown. The ERC-funded AB-AG-INTERACT project aims to develop a high-throughput screening method for over 1 000 Ab paratope-mutated variants binding to more than 1 000 Ag epitope-mutated variants, generating data for over 1 million Ab-Ag binding pairs. This addresses the large-scale sequence and structural data gap. The findings will contribute to a deeper understanding of these rules, advancing the in silico design of antibodies and vaccines.

Objective

Antibody-antigen binding is the basis of two fundamental biotherapeutic pillars: monoclonal antibodies (1) and vaccines (2). To accelerate therapeutics discovery, we need to perform antibody (Ab) and antigen (Ag) design in silico. Specifically, we need to address a fundamental immuno-biotechnological challenge: understanding the interaction rules that predict Ab-Ag binding. Solving this challenge demands the convergence of biotechnology, computational structural biology, and machine learning (ML). My lab is one of the few worldwide to have this transdisciplinary expertise.

Research problem: Currently, the predictive performance of Ab-Ag binding is poor, and an understanding of the underlying rules of Ab-Ag binding is mostly absent. We previously showed that both unprecedentedly large datasets (>10^5 Ab-Ag sequence pairs) and extensive structural information on the Ab-Ag binding interface (paratope, epitope) are needed to increase prediction accuracy and recover binding rules.

Targeted breakthrough: To address the lack of large-scale Ab-Ag sequence and structural data, we will develop a method for high-throughput screening of >10^3 Ab paratope-mutated variants binding to >10^3 of Ag epitope-mutated variants, generating sequence data of Ab-Ag binding pairs at an unprecedented scale (>10^6 sequence Ab-Ag pairs). Structural information of the entirety of the sequence-based Ab-Ag binding data will be generated by building and innovating on recent breakthroughs in computational structural biology. To derive Ab-Ag interaction rules from the generated data, we will develop ML techniques for Ab-Ag binding prediction and rule recovery. We will demonstrate experimentally that we have begun to understand Ab-Ag interaction rules.

Impact: The proposed research generates the exact data necessary to recover the rules of Ab-Ag binding and provides a first groundbreaking insight into those rules, moving us closer to in silico on-demand antibody and vaccine design.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-COG

See all projects funded under this call

Host institution

UNIVERSITETET I OSLO
Net EU contribution
€ 2 000 000,00
Address
PROBLEMVEIEN 5-7
0313 Oslo
Norway
Region
Norge Oslo og Viken Oslo
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 000 000,00

Beneficiaries (1)